Firma Chun Cheong
Concise Prescribing Info
Management of essential HTN, can be used alone or in combination w/ other antihypertensive agents (eg, thiazide-type diuretics). Treatment of angina pectoris. Treatment of stable chronic heart failure of all degrees of severity (ischemic or non-ischemic in origin), as an adjunct to treatment w/ diuretics, ACE inhibitors & optionally digitalis.
Dosage/Direction for Use
Essential HTN Initially 12.5 mg once daily for the 1st 2 days. Thereafter, 25 mg once daily. May be increased at intervals of at least 2 wk to max 50 mg once daily or in divided doses (bd). Elderly Initially 12.5 mg once daily, may be titrated at intervals of at least 2 wk up to max 50 mg once daily or in divided doses. Angina pectoris Initially 12.5 mg bd for the 1st 2 days. Thereafter, 25 mg bd. Thereafter, may be increased at intervals of at least 2 wk up to max 100 mg daily, given in divided doses (bd). Elderly Max 50 mg daily, given in divided doses (bd). Stable chronic heart failure Initially 3.125 mg bd for 2 wk. If tolerated, may be increased at intervals of not less than 2 wk to 6.25 mg, 12.5 mg & 25 mg bd. Max: 25 mg bd for patients w/ severe chronic heart failure & patients w/ mild to moderate chronic heart failure weighing <85 kg (187 lbs); 50 mg bd for patients w/ mild or moderate chronic heart failure weighing >85 kg.
Should be taken with food.
Hypersensitivity. Unstable/decompensated heart failure; clinically manifest liver dysfunction; 2nd & 3rd degree AV block (unless a permanent pacemaker is in place); severe bradycardia (<50 bpm); sick sinus syndrome (including SA block); severe hypotension (systolic BP <85 mmHg); cardiogenic shock; history of bronchospasm or asthma.
Special Precautions
Risk of worsening cardiac failure or fluid retention during up-titration of carvedilol in congestive heart failure patients; reversible deterioration of renal function in chronic heart failure patients w/ low BP (systolic BP <100 mmHg), ischaemic heart disease & diffuse vascular disease, &/or underlying renal insufficiency. Caution in patients w/ COPD w/ bronchospastic component who are not receiving oral or inhaled medication; DM patients; patients w/ peripheral vascular disease; patients suffering from peripheral circulatory disorders (eg, Raynaud's phenomenon); patients undergoing general surgery; patients w/ history of serious hypersensitivity reactions & undergoing desensitisation therapy; history of psoriasis associated w/ β-blocker; patients suspected of having pheochromocytoma; Prinzmetal's variant angina. May obscure symptoms of thyrotoxicosis. May induce bradycardia. Wearers of contact lenses should bear in mind the possibility of reduced lacrimation. Do not discontinue abruptly, particularly in patients w/ ischaemic heart disease. Use w/ caution in combination w/ digitalis glycosides. Careful monitoring of ECG & BP in patients receiving concomitant therapy w/ Ca channel blockers of verapamil or diltiazem type or other antiarrhythmic drugs. Ability to drive, operate machinery, or work w/o firm support may be impaired. Pregnancy. Not recommended if breast-feeding.
Adverse Reactions
Chronic heart failure: Dizziness, headaches; asthenia (including fatigue). Bradycardia, postural hypotension, hypotension, oedema (including generalised, peripheral, dependent & genital oedema, oedema of the legs, hypervolaemia & fluid overload); nausea, diarrhoea, vomiting; wt increase & hypercholesterolemia; hyperglycaemia, hypoglycaemia, worsening control of blood glucose in patients w/ pre-existing DM; vision abnormalities. Essential HTN & long-term management of coronary heart disease: Dizziness, headaches, fatigue; bradycardia, postural hypotension; asthma & dyspnea in predisposed patients; GI upset (w/ symptoms eg, nausea, abdominal pain, diarrhoea); pain in the extremities; reduced lacrimation & eye irritation.
Drug Interactions
Increased bioavailability of P-glycoprotein substrates. Modified bioavailability w/ P-glycoprotein inducers or inhibitors. Modified systemic &/or presystemic metabolism w/ CYP2D6 & CYP2C9 inhibitors or inducers. Increased conc of digoxin; cyclosporin (oral). Decreased plasma levels w/ rifampicin. Decreased clearance of S-carvedilol w/ amiodarone. Increased mean AUC of R-carvedilol w/ fluoxetine. May enhance blood-sugar-reducing effect of insulin & oral hypoglycaemics. Risk of hypotension &/or severe bradycardia w/ catecholamine-depleting agents (eg, reserpine & MAOIs). Additive prolongation of AV conduction time w/ digoxin. Increased risk of AV conduction disturbances w/ verapamil, diltiazem, amiodarone or other antiarrhythmics. Potentiated BP- & heart rate-lowering effects w/ clonidine. Isolated cases of conduction disturbance w/ diltiazem. May potentiate effect of other antihypertensives (eg, α1-receptor antagonists) or drugs that have hypotension as part of their adverse effect profile. Synergistic negative inotropic & hypotensive effects w/ anaesth. Increased BP & lowered BP control w/ NSAIDs. Opposed bronchodilator effects of β-agonist bronchodilators.
MIMS Class
ATC Classification
C07AG02 - carvedilol ; Belongs to the class of alpha and beta blocking agents. Used in the treatment of cardiovascular diseases.
Dilatrend tab 12.5 mg
Dilatrend tab 25 mg
Dilatrend tab 6.25 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in